Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M UNGER

Showing results (561-570 of 604) with videos related to

Pageof 61
Sort By:
JAMA Network Open|April 10, 2026
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerMeghna S Trivedi, Joseph M Unger, N Lynn Henry, et al.
Annals of Neurology|March 14, 2015
Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter studyRonald B Postuma, Alex Iranzo, Birgit Hogl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
Journal of Patient-Reported Outcomes|June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
JAMA Oncology|July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical TrialScott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
JCO Oncology Practice|August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data QualityJoseph M Unger, Hillary Stires, Laura A Levit, et al.
JCO Precision Oncology|September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)Riha Vaidya, Joseph M Unger, Lu Qian, et al.
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.
Journal of Patient-Reported Outcomes|July 10, 2020
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013Siu-Fun Wong, Joseph M Unger, James L Wade, et al.
Blood|February 21, 2004
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectLisa M Rimsza, Robin A Roberts, Thomas P Miller, et al.
Pageof 61

Showing results (561-570 of 604) with videos related to

Sort By:
Pageof 61
JAMA Network Open|April 10, 2026
Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage CancerMeghna S Trivedi, Joseph M Unger, N Lynn Henry, et al.
Annals of Neurology|March 14, 2015
Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter studyRonald B Postuma, Alex Iranzo, Birgit Hogl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
Journal of Patient-Reported Outcomes|June 29, 2018
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)Joseph M Unger, Katherine Griffin, Gary W Donaldson, et al.
JAMA Oncology|July 15, 2021
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical TrialScott N Gettinger, Mary W Redman, Lyudmila Bazhenova, et al.
JCO Oncology Practice|August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data QualityJoseph M Unger, Hillary Stires, Laura A Levit, et al.
JCO Precision Oncology|September 7, 2023
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)Riha Vaidya, Joseph M Unger, Lu Qian, et al.
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.
Journal of Patient-Reported Outcomes|July 10, 2020
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013Siu-Fun Wong, Joseph M Unger, James L Wade, et al.
Blood|February 21, 2004
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling ProjectLisa M Rimsza, Robin A Roberts, Thomas P Miller, et al.
Pageof 61